Breast Cancer's $25 Trillion Miracle—and Why It's at Risk

Not long ago, a breast cancer diagnosis often meant an uncertain and frightening future. Today, thanks to decades of relentless American medical innovation, that fear has increasingly been replaced by hope and survival.

In the past 30 years, breakthroughs in breast cancer treatment have transformed this once-dreaded disease into a largely survivable condition for millions of women. According to a new report from the U.S. Chamber of Commerce on the Full Value of Medical Innovation, these advances have not only saved countless lives, but they also generated astonishing benefits for our society and economy. When we invest in medical innovation, we all win. But if we choke off the innovation pipeline with short-sighted policies like failed foreign price controls, we risk losing immeasurable human and economic value.

A Triumph of Survival

In the early 1990s, the odds of a woman dying from breast cancer were nearly double what they are now. Today, the overall five-year survival is about 91%, and the study found that breast cancer survivors are living roughly seven years longer, on average, than a generation ago. Seven extra years to watch children grow up, meet grandchildren, and pursue careers and dreams.

Breast cancer is among the most common cancers in America—one in every eight women will be diagnosed in her lifetime. The chance of an American woman dying of breast cancer has fallen by about 44% since 1989. Those percentage points represent real people: mothers, grandparents, entrepreneurs, community leaders, and mentors who are alive today because of medical breakthroughs.

$25 Trillion and Counting

The U.S. Chamber's analysis finds that advances in breast cancer treatment have created about $25 trillion worth of health gains over the last 30 years, roughly equal to the entire annual output of the U.S. economy. That translates to nearly $800 billion in value every single year, above and beyond whatever treatments may cost.

Longer survival also delivers meaningful economic benefits. Successful treatments allow women to continue thriving in their chosen careers and to remain an active contributor in their community. The report estimates that breast cancer breakthroughs have added about $1.2 trillion in economic output over 30 years, roughly $40 billion in additional productivity annually, thanks to survivors who remained in the workforce. When survivors thrive, so do their families and local economies.

Don't Break the Innovation Engine

This progress didn't happen by accident. It happened because the United States nurtured an innovation ecosystem capable of producing breakthrough after breakthrough: sustained R&D investment, strong intellectual property rights, and a market that rewards risk-taking in medicine. American researchers and companies tackled the hardest problems in oncology through trial and error, gradually improving therapies and survival rates. This model works.

Unfortunately, we risk forgetting this lesson just when we need it most. As healthcare costs pressure policymakers, there's growing temptation to slash drug prices through heavy-handed intervention, like adopting a "Most Favored Nation" pricing rule to cap U.S. prices based on the prices paid abroad. Other nations may pay less by free-riding on American innovation, but those artificially low prices discourage the very innovation that produces new cures. Countries with strict price controls develop fewer breakthrough therapies and often wait longer to access new treatments.

The study makes it crystal clear: if we adopt policies that undermine research incentives, adopting failed foreign price-caps, weakening patents, or failing to encourage innovators, we will forfeit future gains. Any short-term savings would be dwarfed by long-term losses in lives cut short, economic potential unrealized, and new treatments and technologies never created.

Instead, we need to double down on what works: preserving market-based incentives, upholding strong intellectual property rights, and keeping our focus on long-term value over short-term cost-cutting. We can find ways to make medicines more affordable without killing the goose that lays the golden eggs.

In the end, supporting medical innovation means supporting our moms, sisters, friends, and co-workers. It's about making sure a diagnosis that once brought despair now brings a fighting chance and understanding that the cost of curing disease is far less than the cost of enduring it.

About the author

Kelly Anderson

Kelly Anderson serves as vice president of international policy at the U.S. Chamber’s Global Innovation Policy Center (GIPC). Anderson oversees the GIPC’s global advocacy efforts and leads the GIPC’s policy engagement in the multilateral organizations and developed economies.

Read more